SLC7A11 and neoplasm: Inhibition of xCT or disruption of the CD44v–xCT interaction depletes CD44v-expressing tumor cells and sensitizes them to oxidative stress, suggesting that CD44v-directed therapies could modulate redox-sensitive pathology [27,162].